Eurofins Discovery Releases Publication on Molecular Mechanism of BTK Inhibitors
NEWS PROVIDED BY:
Eurofins Discovery
SAN DIEGO, CA – May 2, 2024 — Eurofins Discovery, an industry-leading provider of products and services for drug discovery announced today a latest publication in ACS Pharmacology & Translational Science Journal, titled “Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-Covalent Mechanisms.”
This study dives into the molecular mechanisms of BTK inhibitors, focusing on their specificity, potency, and biological effects. The publication also explores both covalent and non-covalent binding interactions, providing key insights to enhance drug discovery and target development. Highlights include in-depth analysis of BTK inhibitor selectivity, mechanistic differences between binding modalities, and evaluation of biological responses using Eurofins Discovery’s KINOMEscan® platform and BioMAP® Diversity Plus® panel.
Access the full manuscript here: https://pubs.acs.org/doi/10.1021/acsptsci.4c00540
For further information:
Mirza Jahic, Associate Director
Mirza.Jahic@discovery.eurofinsus.com
About Eurofins Discovery
Eurofins Discovery supports drug discovery research with over 23,000 products and services developed in 40+ years of industry leadership. Benefit from the strength of our solutions that revolutionize your drug discovery.
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
